@Article{Nowicki2020,
journal="Alergologia Polska - Polish Journal of Allergology",
issn="2353-3854",
volume="7",
number="4",
year="2020",
title="Biological drugs in the treatment of atopic dermatitis – recommendations of the Polish Dermatological Society, 
the Polish Society of Allergology, the Polish Pediatric Society 
and the Polish Society of Family Medicine",
abstract="The basis for development of atopic dermatitis are genetic, immunological and microbiological abnormalities  as well as epidermal barrier defects. The course of the disease includes periodic exacerbations and remissions. Its development and course are influenced by numerous environmental and individual factors. In recent decades, in industrialized countries, a threefold increase in the incidence of atopic dermatitis was observed. There also is an increasing number of cases resistant to topical treatment. Effective treatment of atopic dermatitis should provide control of clinical symptoms, prevent exacerbations and improve the quality of life of patients. The multifactorial etiopathogenesis and various endotypes and phenotypes of the disease justify the tendency to optimize and personalize the therapy. Currently, we recommend the use of dupilumab for the treatment of patients from 12 years of age with moderate and severe atopic dermatitis, who do not respond to topical treatment.",
author="Nowicki, Roman
and Trzeciak, Magdalena
and Rudnicka, Lidia
and Szepietowski, Jacek
and Kulus, Marek
and Kupczyk, Maciej
and Mastalerz-Migas, Agnieszka
and Peregud-Pogorzelski, Jarosław
and Jahnz-Różyk, Karina
and Narbutt, Joanna
and Czarnecka-Operacz, Magdalena
and Czajkowski, Rafal
and Grubska-Suchanek, Elżbieta
and Krasowska, Dorota
and Kręcisz, Beata
and Kowalewski, Cezary
and Lesiak, Aleksandra
and Olszewska, Malgorzata
and Samochocki, Zbigniew
and Śpiewak, Radosław
and Wilkowska, Aleksandra",
pages="171--179",
doi="10.5114/pja.2020.102084",
url="http://dx.doi.org/10.5114/pja.2020.102084"
}